MA09-hRPE
Pre-clinicalCompleted 0 watching 0 views this week💤 Quiet
23
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Age-Related Macular Degeneration
Conditions
Age-Related Macular Degeneration
Trial Timeline
Feb 25, 2013 → Aug 19, 2019
NCT ID
NCT02463344About MA09-hRPE
MA09-hRPE is a pre-clinical stage product being developed by Astellas Pharma for Age-Related Macular Degeneration. The current trial status is completed. This product is registered under clinical trial identifier NCT02463344. Target conditions include Age-Related Macular Degeneration.
Hype Score Breakdown
Clinical
5
Activity
2
Company
10
Novelty
2
Community
1
Clinical Trials (5)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02463344 | Pre-clinical | Completed |
| NCT02445612 | Pre-clinical | Completed |
| NCT01469832 | Phase 1/2 | Completed |
| NCT01345006 | Phase 1/2 | Completed |
| NCT01344993 | Phase 1/2 | Completed |
Competing Products
20 competing products in Age-Related Macular Degeneration